Oxbryta (voxelotor) is a first-in-class oral hemoglobin oxygen affinity modulator that is believed to target and bind to the N-terminal valine of the alpha chain of hemoglobin S (HbS). This improves hemoglobin oxygen affinity and consequently inhibits HbS polymerization, thereby reducing sickling and hemolysis, and increasing the half-life of red blood cells. This is believed to ultimately improve blood flow and decrease hemolytic anemia in patients with sickle cell disease.
If you have a Hayes login, click here to view the full report on the Knowledge Center.